Dexcom CONNECT Study: The Most Significant Clinical Study Demonstrating CGM Benefits for People with Type 2 Diabetes Not Using Insulin

DexCom, Inc. (NASDAQ:DXCM) announced today results from the CONNECT randomized controlled trial, demonstrating the use of ...
Drug Delivery Business

Dexcom study highlights benefits of G7 CGM in non-insulin type 2 diabetes

Dexcom (Nasdaq:DXCM) today announced findings from a study demonstrating the benefits of its G7 CGM in type 2 diabetes.

Dexcom's glucose monitor use shows benefit in non-insulin diabetic patients in study

By Sneha S K June 6 (Reuters) - Medical device maker Dexcom said the use of its continuous glucose monitor, G7, led to ...
Zacks Investment Research on MSN

Dexcom reports positive CONNECT data for non-insulin diabetes

DexCom, Inc. DXCM recently announced positive results from its CONNECT randomized controlled trial, demonstrating that use of ...

Dexcom bolsters evidence for glucose sensors for Type 2 diabetes

New study results could lead to better insurance coverage of the devices for people who don’t take insulin, a researcher said ...
Medscape

New Dexcom G7 Feature Cleared as 15-day Sensor Set to Launch

The US FDA has cleared a new “basal insulin dose optimizer” function for the Dexcom G7 15-day continuous glucose monitor (CGM), which is set to launch separately on December 1, 2025. The “Smart Basal” ...